UnicoCell Biomed Past Earnings Performance
Past criteria checks 0/6
UnicoCell Biomed has been growing earnings at an average annual rate of 3.2%, while the Biotechs industry saw earnings growing at 19.2% annually. Revenues have been growing at an average rate of 22.7% per year.
Key information
3.2%
Earnings growth rate
19.4%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 22.7% |
| Return on equity | -14.1% |
| Net Margin | -342.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How UnicoCell Biomed makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 25 | -84 | 31 | 83 |
| 30 Sep 23 | 21 | -84 | 28 | 82 |
| 30 Jun 23 | 18 | -85 | 25 | 80 |
| 31 Mar 23 | 16 | -88 | 25 | 78 |
| 31 Dec 22 | 14 | -91 | 25 | 75 |
| 30 Sep 22 | 13 | -85 | 26 | 69 |
| 30 Jun 22 | 13 | -79 | 26 | 64 |
| 31 Mar 22 | 10 | -83 | 25 | 67 |
| 31 Dec 21 | 8 | -86 | 23 | 70 |
| 30 Sep 21 | 7 | -94 | 23 | 77 |
| 30 Jun 21 | 6 | -102 | 22 | 84 |
| 31 Mar 21 | 5 | -106 | 22 | 88 |
| 31 Dec 20 | 4 | -109 | 22 | 92 |
| 30 Sep 20 | 8 | -107 | 22 | 92 |
| 30 Jun 20 | 11 | -105 | 22 | 92 |
| 31 Mar 20 | 14 | -103 | 21 | 93 |
| 31 Dec 19 | 16 | -101 | 20 | 94 |
| 31 Dec 18 | 5 | -69 | 7 | 66 |
| 31 Dec 17 | 6 | -43 | 0 | 49 |
Quality Earnings: 6794 is currently unprofitable.
Growing Profit Margin: 6794 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6794 is unprofitable, but has reduced losses over the past 5 years at a rate of 3.2% per year.
Accelerating Growth: Unable to compare 6794's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6794 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.8%).
Return on Equity
High ROE: 6794 has a negative Return on Equity (-14.1%), as it is currently unprofitable.